A novel clinically relevant strategy to abrogate autoimmunity and regulate alloimmunity in NOD mice

Andrea Vergani, Francesca D'Addio, Mollie Jurewicz, Alessandra Petrelli, Toshihiko Watanabe, Kaifeng Liu, Kenneth Law, Christian Schuetz, Michele Carvello, Elena Orsenigo, Shaoping Deng, Scott J. Rodig, Javeed M. Ansari, Carlo Staudacher, Reza Abdi, John Williams, James Markmann, Mark Atkinson, Mohamed H. Sayegh, Paolo Fiorina

Research output: Contribution to journalArticle

Abstract

OBJECTIVE - To investigate a new clinically relevant immunoregulatory strategy based on treatment with murine Thymoglobulin mATG Genzyme and CTLA4-Ig in NOD mice to prevent alloand autoimmune activation using a stringent model of islet transplantation and diabetes reversal. RESEARCH DESIGN AND METHODS - Using allogeneic islet transplantation models as well as NOD mice with recent onset type 1 diabetes, we addressed the therapeutic efficacy and immunomodulatory mechanisms associated with a new immunoregulatory protocol based on prolonged low-dose mATG plus CTLA4-Ig. RESULTS - BALB/c islets transplanted into hyperglycemic NOD mice under prolonged mATG+CTLA4-Ig treatment showed a pronounced delay in allograft rejection compared with untreated mice (mean survival time: 54 vs. 8 days, P <0.0001). Immunologic analysis of mice receiving transplants revealed a complete abrogation of autoimmune responses and severe downregulation of alloimmunity in response to treatment. The striking effect on autoimmunity was confirmed by 100% diabetes reversal in newly hyperglycemic NOD mice and 100% indefinite survival of syngeneic islet transplantation (NOD.SCID into NOD mice). CONCLUSIONS - The capacity to regulate alloimmunity and to abrogate the autoimmune response in NOD mice in different settings confirmed that prolonged mATG+CTLA4-Ig treatment is a clinically relevant strategy to translate to humans with type 1 diabetes.

Original languageEnglish
Pages (from-to)2253-2264
Number of pages12
JournalDiabetes
Volume59
Issue number9
DOIs
Publication statusPublished - 2010

Fingerprint

Inbred NOD Mouse
Autoimmunity
Islets of Langerhans Transplantation
Obese Mice
Type 1 Diabetes Mellitus
Isogeneic Transplantation
Therapeutics
Homologous Transplantation
Allografts
Research Design
Down-Regulation
Transplants
Survival
Abatacept

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)

Cite this

Vergani, A., D'Addio, F., Jurewicz, M., Petrelli, A., Watanabe, T., Liu, K., ... Fiorina, P. (2010). A novel clinically relevant strategy to abrogate autoimmunity and regulate alloimmunity in NOD mice. Diabetes, 59(9), 2253-2264. https://doi.org/10.2337/db09-1264

A novel clinically relevant strategy to abrogate autoimmunity and regulate alloimmunity in NOD mice. / Vergani, Andrea; D'Addio, Francesca; Jurewicz, Mollie; Petrelli, Alessandra; Watanabe, Toshihiko; Liu, Kaifeng; Law, Kenneth; Schuetz, Christian; Carvello, Michele; Orsenigo, Elena; Deng, Shaoping; Rodig, Scott J.; Ansari, Javeed M.; Staudacher, Carlo; Abdi, Reza; Williams, John; Markmann, James; Atkinson, Mark; Sayegh, Mohamed H.; Fiorina, Paolo.

In: Diabetes, Vol. 59, No. 9, 2010, p. 2253-2264.

Research output: Contribution to journalArticle

Vergani, A, D'Addio, F, Jurewicz, M, Petrelli, A, Watanabe, T, Liu, K, Law, K, Schuetz, C, Carvello, M, Orsenigo, E, Deng, S, Rodig, SJ, Ansari, JM, Staudacher, C, Abdi, R, Williams, J, Markmann, J, Atkinson, M, Sayegh, MH & Fiorina, P 2010, 'A novel clinically relevant strategy to abrogate autoimmunity and regulate alloimmunity in NOD mice', Diabetes, vol. 59, no. 9, pp. 2253-2264. https://doi.org/10.2337/db09-1264
Vergani A, D'Addio F, Jurewicz M, Petrelli A, Watanabe T, Liu K et al. A novel clinically relevant strategy to abrogate autoimmunity and regulate alloimmunity in NOD mice. Diabetes. 2010;59(9):2253-2264. https://doi.org/10.2337/db09-1264
Vergani, Andrea ; D'Addio, Francesca ; Jurewicz, Mollie ; Petrelli, Alessandra ; Watanabe, Toshihiko ; Liu, Kaifeng ; Law, Kenneth ; Schuetz, Christian ; Carvello, Michele ; Orsenigo, Elena ; Deng, Shaoping ; Rodig, Scott J. ; Ansari, Javeed M. ; Staudacher, Carlo ; Abdi, Reza ; Williams, John ; Markmann, James ; Atkinson, Mark ; Sayegh, Mohamed H. ; Fiorina, Paolo. / A novel clinically relevant strategy to abrogate autoimmunity and regulate alloimmunity in NOD mice. In: Diabetes. 2010 ; Vol. 59, No. 9. pp. 2253-2264.
@article{191fc82c7b2046b59b74ad0afe576a1d,
title = "A novel clinically relevant strategy to abrogate autoimmunity and regulate alloimmunity in NOD mice",
abstract = "OBJECTIVE - To investigate a new clinically relevant immunoregulatory strategy based on treatment with murine Thymoglobulin mATG Genzyme and CTLA4-Ig in NOD mice to prevent alloand autoimmune activation using a stringent model of islet transplantation and diabetes reversal. RESEARCH DESIGN AND METHODS - Using allogeneic islet transplantation models as well as NOD mice with recent onset type 1 diabetes, we addressed the therapeutic efficacy and immunomodulatory mechanisms associated with a new immunoregulatory protocol based on prolonged low-dose mATG plus CTLA4-Ig. RESULTS - BALB/c islets transplanted into hyperglycemic NOD mice under prolonged mATG+CTLA4-Ig treatment showed a pronounced delay in allograft rejection compared with untreated mice (mean survival time: 54 vs. 8 days, P <0.0001). Immunologic analysis of mice receiving transplants revealed a complete abrogation of autoimmune responses and severe downregulation of alloimmunity in response to treatment. The striking effect on autoimmunity was confirmed by 100{\%} diabetes reversal in newly hyperglycemic NOD mice and 100{\%} indefinite survival of syngeneic islet transplantation (NOD.SCID into NOD mice). CONCLUSIONS - The capacity to regulate alloimmunity and to abrogate the autoimmune response in NOD mice in different settings confirmed that prolonged mATG+CTLA4-Ig treatment is a clinically relevant strategy to translate to humans with type 1 diabetes.",
author = "Andrea Vergani and Francesca D'Addio and Mollie Jurewicz and Alessandra Petrelli and Toshihiko Watanabe and Kaifeng Liu and Kenneth Law and Christian Schuetz and Michele Carvello and Elena Orsenigo and Shaoping Deng and Rodig, {Scott J.} and Ansari, {Javeed M.} and Carlo Staudacher and Reza Abdi and John Williams and James Markmann and Mark Atkinson and Sayegh, {Mohamed H.} and Paolo Fiorina",
year = "2010",
doi = "10.2337/db09-1264",
language = "English",
volume = "59",
pages = "2253--2264",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "9",

}

TY - JOUR

T1 - A novel clinically relevant strategy to abrogate autoimmunity and regulate alloimmunity in NOD mice

AU - Vergani, Andrea

AU - D'Addio, Francesca

AU - Jurewicz, Mollie

AU - Petrelli, Alessandra

AU - Watanabe, Toshihiko

AU - Liu, Kaifeng

AU - Law, Kenneth

AU - Schuetz, Christian

AU - Carvello, Michele

AU - Orsenigo, Elena

AU - Deng, Shaoping

AU - Rodig, Scott J.

AU - Ansari, Javeed M.

AU - Staudacher, Carlo

AU - Abdi, Reza

AU - Williams, John

AU - Markmann, James

AU - Atkinson, Mark

AU - Sayegh, Mohamed H.

AU - Fiorina, Paolo

PY - 2010

Y1 - 2010

N2 - OBJECTIVE - To investigate a new clinically relevant immunoregulatory strategy based on treatment with murine Thymoglobulin mATG Genzyme and CTLA4-Ig in NOD mice to prevent alloand autoimmune activation using a stringent model of islet transplantation and diabetes reversal. RESEARCH DESIGN AND METHODS - Using allogeneic islet transplantation models as well as NOD mice with recent onset type 1 diabetes, we addressed the therapeutic efficacy and immunomodulatory mechanisms associated with a new immunoregulatory protocol based on prolonged low-dose mATG plus CTLA4-Ig. RESULTS - BALB/c islets transplanted into hyperglycemic NOD mice under prolonged mATG+CTLA4-Ig treatment showed a pronounced delay in allograft rejection compared with untreated mice (mean survival time: 54 vs. 8 days, P <0.0001). Immunologic analysis of mice receiving transplants revealed a complete abrogation of autoimmune responses and severe downregulation of alloimmunity in response to treatment. The striking effect on autoimmunity was confirmed by 100% diabetes reversal in newly hyperglycemic NOD mice and 100% indefinite survival of syngeneic islet transplantation (NOD.SCID into NOD mice). CONCLUSIONS - The capacity to regulate alloimmunity and to abrogate the autoimmune response in NOD mice in different settings confirmed that prolonged mATG+CTLA4-Ig treatment is a clinically relevant strategy to translate to humans with type 1 diabetes.

AB - OBJECTIVE - To investigate a new clinically relevant immunoregulatory strategy based on treatment with murine Thymoglobulin mATG Genzyme and CTLA4-Ig in NOD mice to prevent alloand autoimmune activation using a stringent model of islet transplantation and diabetes reversal. RESEARCH DESIGN AND METHODS - Using allogeneic islet transplantation models as well as NOD mice with recent onset type 1 diabetes, we addressed the therapeutic efficacy and immunomodulatory mechanisms associated with a new immunoregulatory protocol based on prolonged low-dose mATG plus CTLA4-Ig. RESULTS - BALB/c islets transplanted into hyperglycemic NOD mice under prolonged mATG+CTLA4-Ig treatment showed a pronounced delay in allograft rejection compared with untreated mice (mean survival time: 54 vs. 8 days, P <0.0001). Immunologic analysis of mice receiving transplants revealed a complete abrogation of autoimmune responses and severe downregulation of alloimmunity in response to treatment. The striking effect on autoimmunity was confirmed by 100% diabetes reversal in newly hyperglycemic NOD mice and 100% indefinite survival of syngeneic islet transplantation (NOD.SCID into NOD mice). CONCLUSIONS - The capacity to regulate alloimmunity and to abrogate the autoimmune response in NOD mice in different settings confirmed that prolonged mATG+CTLA4-Ig treatment is a clinically relevant strategy to translate to humans with type 1 diabetes.

UR - http://www.scopus.com/inward/record.url?scp=77956377698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956377698&partnerID=8YFLogxK

U2 - 10.2337/db09-1264

DO - 10.2337/db09-1264

M3 - Article

C2 - 20805386

AN - SCOPUS:77956377698

VL - 59

SP - 2253

EP - 2264

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 9

ER -